Christopher U.  Missling net worth and biography

Christopher Missling Biography and Net Worth

Dr. Missling, President and CEO of Anavex, has over 20 years of healthcare industry experience within large pharmaceutical companies, the biotech industry and investment banking. Prior to joining Anavex®, he served as the Chief Financial Officer of Curis and ImmunoGen. In addition, at Aventis (now Sanofi),  Dr. Missling worked as head of financial planning on all aspects of financial strategy and M&A. His career experience also includes working as an investment banker in the healthcare practice at Deutsche Bank, serving pharmaceutical, biotech, and diagnostic companies, as well as serving as the head of healthcare investment banking at Brimberg & Co. in New York. Dr. Missling has an MS and PhD from the University of Munich in Chemistry and an MBA from Northwestern University Kellogg School of Management.

What is Christopher U. Missling's net worth?

The estimated net worth of Christopher U. Missling is at least $5.56 million as of March 28th, 2024. Dr. Missling owns 1,250,210 shares of Anavex Life Sciences stock worth more than $5,563,435 as of December 5th. This net worth approximation does not reflect any other assets that Dr. Missling may own. Additionally, Dr. Missling receives an annual salary of $828,250.00 as CEO at Anavex Life Sciences. Learn More about Christopher U. Missling's net worth.

How old is Christopher U. Missling?

Dr. Missling is currently 58 years old. There are 1 older executives and no younger executives at Anavex Life Sciences. Learn More on Christopher U. Missling's age.

What is Christopher U. Missling's salary?

As the CEO of Anavex Life Sciences Corp., Dr. Missling earns $828,250.00 per year. Learn More on Christopher U. Missling's salary.

How do I contact Christopher U. Missling?

The corporate mailing address for Dr. Missling and other Anavex Life Sciences executives is 51 W 52ND STREET 7TH FLOOR, NEW YORK NY, 10019. Anavex Life Sciences can also be reached via phone at (844) 689-3939 and via email at [email protected]. Learn More on Christopher U. Missling's contact information.

Has Christopher U. Missling been buying or selling shares of Anavex Life Sciences?

Christopher U. Missling has not been actively trading shares of Anavex Life Sciences within the last three months. Most recently, Christopher U. Missling sold 73,380 shares of the business's stock in a transaction on Thursday, March 28th. The shares were sold at an average price of $5.11, for a transaction totalling $374,971.80. Following the completion of the sale, the chief executive officer now directly owns 1,250,210 shares of the company's stock, valued at $6,388,573.10. Learn More on Christopher U. Missling's trading history.

Who are Anavex Life Sciences' active insiders?

Anavex Life Sciences' insider roster includes Sandra Boenisch (Treasurer), Peter Donhauser (Director), Elliot Favus (Director), Elliot Favus (Director), Christopher Missling (CEO), and Steffen Thomas (Director). Learn More on Anavex Life Sciences' active insiders.

Christopher U. Missling Insider Trading History at Anavex Life Sciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/28/2024Sell73,380$5.11$374,971.801,250,210View SEC Filing Icon  
6/28/2023Sell268,000$7.98$2,138,640.001,018,210View SEC Filing Icon  
3/7/2018Buy1,360$2.92$3,971.20View SEC Filing Icon  
3/5/2018Buy1,500$2.63$3,945.001,015,400View SEC Filing Icon  
3/2/2018Buy1,650$2.41$3,976.501,013,900View SEC Filing Icon  
10/24/2017Buy375$4.92$1,845.001,011,875View SEC Filing Icon  
10/19/2017Buy375$4.49$1,683.751,011,500View SEC Filing Icon  
10/17/2017Buy375$4.27$1,601.25View SEC Filing Icon  
10/13/2017Buy750$4.22$3,165.00View SEC Filing Icon  
10/5/2017Buy375$4.30$1,612.50View SEC Filing Icon  
10/2/2017Buy375$4.20$1,575.001,009,625View SEC Filing Icon  
9/28/2017Buy375$4.21$1,578.751,009,250View SEC Filing Icon  
9/26/2017Buy375$3.88$1,455.001,008,875View SEC Filing Icon  
9/20/2017Buy375$4.23$1,586.251,008,500View SEC Filing Icon  
9/18/2017Buy375$4.40$1,650.001,008,125View SEC Filing Icon  
9/14/2017Buy375$4.58$1,717.501,007,750View SEC Filing Icon  
9/11/2017Buy375$4.81$1,803.751,007,375View SEC Filing Icon  
9/7/2017Buy375$4.76$1,785.001,007,000View SEC Filing Icon  
9/5/2017Buy375$4.90$1,837.501,006,625View SEC Filing Icon  
8/31/2017Buy375$4.48$1,680.001,006,250View SEC Filing Icon  
8/28/2017Buy375$4.44$1,665.001,005,875View SEC Filing Icon  
8/24/2017Buy375$4.54$1,702.501,005,500View SEC Filing Icon  
8/21/2017Buy375$4.07$1,526.251,005,125View SEC Filing Icon  
8/18/2017Buy375$3.81$1,428.751,004,750View SEC Filing Icon  
8/14/2017Buy375$3.70$1,387.501,004,375View SEC Filing Icon  
8/11/2017Buy750$3.55$2,662.501,004,000View SEC Filing Icon  
7/14/2015Buy1,000$0.52$520.00View SEC Filing Icon  
7/13/2015Buy1,000$0.53$530.00View SEC Filing Icon  
7/7/2015Buy2,000$0.49$980.00View SEC Filing Icon  
7/1/2015Buy2,000$0.45$900.00View SEC Filing Icon  
6/23/2015Buy1,000$0.47$470.00View SEC Filing Icon  
6/22/2015Buy1,000$0.42$420.00View SEC Filing Icon  
6/16/2015Buy1,000$0.44$440.00View SEC Filing Icon  
6/15/2015Buy1,000$0.43$430.00View SEC Filing Icon  
6/10/2015Buy1,000$0.36$360.00View SEC Filing Icon  
6/8/2015Buy1,000$0.35$350.00View SEC Filing Icon  
6/4/2015Buy1,000$0.37$370.00View SEC Filing Icon  
See Full Table

Christopher U. Missling Buying and Selling Activity at Anavex Life Sciences

This chart shows Christopher U Missling's buying and selling at Anavex Life Sciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Anavex Life Sciences Company Overview

Anavex Life Sciences logo
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
Read More

Today's Range

Now: $4.45
Low: $4.29
High: $4.58

50 Day Range

MA: $7.03
Low: $3.08
High: $9.96

2 Week Range

Now: $4.45
Low: $2.86
High: $14.44

Volume

1,867,670 shs

Average Volume

4,467,153 shs

Market Capitalization

$397.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.15